Itraconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Itraconazole: From Systemic Fungal Infections to Pneumocystosis
One-Sentence Summary
Itraconazole is a triazole antifungal internationally indicated for systemic and invasive fungal infections such as aspergillosis, candidiasis, and histoplasmosis. The TxGNN model predicts it may be effective for Pneumocystosis (Pneumocystis jirovecii infection), with no dedicated clinical trials and 20 publications currently offering only indirect supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the available regulatory data; internationally itraconazole is indicated for systemic/invasive fungal infections (aspergillosis, candidiasis, histoplasmosis, blastomycosis) |
| Predicted New Indication | Pneumocystosis |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L4 (mechanism/indirect evidence only) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for itraconazole was not available in this evidence pack. Based on known pharmacology, itraconazole is a triazole antifungal that inhibits fungal CYP450 lanosterol 14α-demethylase, blocking ergosterol synthesis in the fungal cell membrane — its efficacy against classical fungi (Aspergillus, Candida, Histoplasma) is well established.
However, Pneumocystis jirovecii is an atypical fungus whose membrane relies primarily on host-derived cholesterol rather than self-synthesized ergosterol. A mechanistic study in the evidence pool (PMID 12606318) found that Pneumocystis carinii’s lanosterol 14α-demethylase differs from azole-susceptible organisms, consistent with the organism’s known intrinsic resistance to azole antifungals. This means the standard triazole mechanism is unlikely to translate directly into anti-Pneumocystis activity.
Most of the supporting literature places itraconazole in the context of broad-spectrum antifungal prophylaxis for immunocompromised patients (HIV, transplant recipients), where it is co-administered or co-discussed alongside pneumocystosis prevention rather than used as direct treatment for P. jirovecii. The TxGNN score of 99.34% likely reflects a strong co-occurrence pathway in the knowledge graph (itraconazole – immunocompromised host – opportunistic infection) rather than a validated pharmacological mechanism against P. jirovecii specifically. This distinction is important: the prediction is biologically plausible as a research signal but does not currently indicate direct causal efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11737382 | 2001 | RCT | HIV Medicine | Double-blind, placebo-controlled Phase 3 trial of itraconazole capsules for prevention of deep fungal infections in HIV-infected patients; did not specifically isolate pneumocystosis outcomes |
| 21418688 | 2010 | Review | BMJ Clinical Evidence | Reviews primary/secondary prophylaxis for opportunistic infections in HIV, including Pneumocystis, in the context of antifungal/antimicrobial strategies |
| 2121456 | 1990 | Review | Drugs | Summarizes therapy and prophylaxis for Pneumocystis carinii and other protozoan/opportunistic infections, including mode of action and dosing of available agents |
| 8397916 | 1993 | Review | Current Clinical Topics in Infectious Diseases | Discusses prophylaxis and treatment strategies for infections, including fungal, in bone marrow transplant recipients |
| 8016481 | 1993 | Review | Seminars in Respiratory Infections | Reviews infection risk and management, including fungal pneumonia, after lung transplantation |
| 30429396 | 2018 | Cohort | Indian J Medical Microbiology | Compares respiratory fungal pathogen profiles and susceptibility between immunocompetent and immunocompromised hosts by CD4 count |
| 26036497 | 2015 | Cohort | Transplantation Proceedings | Single-center experience of invasive fungal infections after kidney transplantation |
| 12606318 | 2003 | Mechanistic study | Am J Respir Cell Mol Biol | Characterizes lanosterol 14α-demethylase from Pneumocystis carinii; notes intrinsic resistance of Pneumocystis to azole antifungals — directly relevant to mechanistic plausibility |
| 36891307 | 2023 | Case report | Frontiers in Immunology | Reports unusual Talaromyces marneffei and Pneumocystis jirovecii coinfection in a child with STAT1 mutation |
| 7877856 | 1994 | Case report/Review | Pathologie-Biologie | Reviews aspergillosis in AIDS patients, noting prior pneumocystosis as a predisposing clinical context |
South Africa Market Information
Itraconazole currently has no SAHPRA product registrations and is classified as not marketed in South Africa (0 licenses on record). No product name, dosage form, or approved indication text is available from the regulatory data source.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence linking itraconazole to pneumocystosis is indirect — it consists of co-occurrence in prophylaxis literature rather than direct treatment/prevention trials, and a mechanistic study suggests P. jirovecii is intrinsically less susceptible to azole action than classical fungi. Combined with the absence of dedicated clinical trials, unknown MOA/safety data, and the drug’s unregistered status in South Africa, the evidence does not yet support progression beyond a research hold.
To proceed, the following is needed:
- Confirmed mechanism-of-action data from DrugBank/PI to validate or refute applicability to P. jirovecii
- SAHPRA Professional Information (warnings, contraindications, DDI) once/if a registration application is filed
- Direct clinical or preclinical evidence testing itraconazole specifically against Pneumocystis jirovecii (treatment or prophylaxis), compared with standard-of-care (e.g., TMP-SMX)
- Clarification of South Africa market entry pathway, given the current “not marketed” / 0-registration status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.